IMPAACT Developmental Immunology Laboratories

1
IMPAACT Developmental Immunology Laboratories
2
GOALS

• Define important scientific questions that would
  benefit from immunology laboratory investigation
• Review the protocol pipeline
• Identify state-of-the-art technologies and
  laboratory assays that will facilitate
  patient-oriented laboratory investigation and
  support clinical trials, recognizing that future
  studies will increasingly be done in
  resource-limited settings
• Integrate efforts with other IMPAACT laboratory
  investigators and external groups (other Clinical
  Trials Networks, CHAVI, the Global Vaccine
  Enterprise, etc).

3
IMPAACT Priority Areas

• PMTCT
• Vaccine
• Translational
• Optimization

4
Vaccine Specific Aims

• Develop and evaluate safe, cost effective
  approaches to interrupt breastmilk MTCT, prevent
  sexual transmission of HIV-1, or treat HIV
  infection
• Vaccines
• Mab
• Immunomodulatory agents
• Evaluate novel vaccines or immunomodulatory
  agents for efficacy in preventing or treating
  co-infections

5
PMTCT/Vaccines

• Pathogenesis
• Better define pathogenesis of infection process
  in women and infants
• Human studies Genetic and biologic
  characterization of infecting viral strains
  across clades
• Correlates of immune protection
• Desirable targets of vaccine-induced immune
  responses
• Maternal and infant immune responses to infection
• Clinical
• Prep studies (e.g., Ad5 seroprevalennce)
• Phase I Clinical Trials to test MAb and vaccines
• Continue to probe pathogenesis
• Prepare for vaccine efficacy trials

6
(No Transcript)
7
Translational/Optimization

• Pathogenesis
• Mechanisms of CD4 depletion
• Immune preservation vs. immune reconstitution
• Protective immunity to routine childhood vaccines
  and common causes of infant/child morbidity and
  mortality
• Pathogenesis of immune reconstitution syndromes

8
Translational

• Combine ART with vaccines or immune modulators to
  optimize control of viral replication and prevent
  disease progression, while sparing exposure to
  ART
• P1033

9
Translational/Optimization

• Develop new vaccines, prophylactic regimens, and
  therapies to prevent or treat OIs
• Pneumonia
• Diarrheal diseases (CS 4060 Ph I Rotavirus)
• TB (P1041 INH prophylaxis)
• Malaria (P1060 Primary Rx malaria)
• HPV (P1047)
• PCP

10
(No Transcript)